Novartis AG ADR (NVS)vsVanda Pharmaceuticals Inc (VNDA)
NVS
Novartis AG ADR
$160.32
-0.04%
HEALTHCARE · Cap: $303.67B
VNDA
Vanda Pharmaceuticals Inc
$3.95
-4.82%
HEALTHCARE · Cap: $230.99M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 24919% more annual revenue ($57.36B vs $229.28M). NVS leads profitability with a 17.5% profit margin vs -119.9%. VNDA appears more attractively valued with a PEG of 2.23. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
VNDA
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.8%
Fair Value
$95.76
Current Price
$160.32
$64.56 premium
Margin of Safety
+83.7%
Fair Value
$37.45
Current Price
$3.95
$33.50 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.3%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 24.1% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Smaller company, higher risk/reward
Weak financial health signals
ROE of -60.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : VNDA
The strongest argument for VNDA centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 24.1% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : VNDA
The primary concerns for VNDA are PEG Ratio, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while VNDA is a growth play — different risk/reward profiles.
VNDA carries more volatility with a beta of 0.73 — expect wider price swings.
VNDA is growing revenue faster at 24.1% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 42/100), backed by strong 17.5% margins. VNDA offers better value entry with a 83.7% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Vanda Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?